Overview

* Rockwell Medical ( RMTI ) Q3 net sales fell 44% yr/yr, missing analyst expectations

* Company achieved profitability on an adjusted EBITDA basis for Q3 2025

* Rockwell Medical's ( RMTI ) cash position increased to $23.7 mln at September 30, 2025

Outlook

* Rockwell Medical ( RMTI ) reiterates 2025 net sales guidance of $65 mln to $70 mln

* Company expects 2025 gross margin between 16% and 18%

* Rockwell Medical ( RMTI ) projects 2025 adjusted EBITDA between ($0.5) mln and $0.5 mln

Result Drivers

* CUSTOMER LOSS - Net sales decreased due to largest customer transitioning to another supplier

* NEW AGREEMENTS - Co signed new long-term product purchasing agreements with medical centers and hospital systems

* OPERATIONAL EFFICIENCY - Co focused on right-sizing organization to enhance operational efficiency and support growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Miss $15.93 $16.20

mln mln (2

Analysts

)

Q3 EPS -$0.05

Q3 Net -$1.75

Income mln

Q3 Gross $2.27

Profit mln

Q3 -$1.58

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Rockwell Medical Inc ( RMTI ) is $4.00, about 73.8% above its November 11 closing price of $1.05

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)